Marsden John, Goetz Camille, Meynen Tim, Mitcheson Luke, Stillwell Garry, Eastwood Brian, Strang John, Grey Nick
Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom.
South London and Maudsley NHS Mental Health Foundation Trust, United Kingdom.
Contemp Clin Trials Commun. 2017 Nov 2;8:264-273. doi: 10.1016/j.conctc.2017.10.009. eCollection 2017 Dec.
Cocaine use disorder (CUD) is a debilitating condition characterised by maladaptive cocaine-related memories and impaired cognitive and behavioural control. There are no evidence-supported pharmacotherapies and only weakly effective psychological interventions specific for CUD. Our novel Memory-focused Cognitive Therapy (MFCT) aims to modify cocaine-related memories to reduce craving and drug use.
This is a single-centre (outpatient), 15-week, two-arm, pilot randomised controlled trial (RCT) to address feasibility, safety, quality and preliminary efficacy. Thirty participants (adults ≥18 years; current CUD) will receive ongoing standard care (treatment-as-usual [TAU]) during the study and will be randomised (1:1) to a control or intervention group. The control group will receive 3 × 90min CUD cognitive case conceptualisation assessments and 2 × 30min cocaine-related cue-induction procedures ( presentation of images and objects). Experimental group participants will receive 3 × 90min CUD cognitive case conceptualisation assessments; 2 × 30min cue-induction procedures; and individual MFCT (5 × 120min; daily for 1 week; with 3 relapse prevention follow-ups over 3-months). All study participants will complete research follow-ups at 1-week, 1-month and 3-months. The experimental and control groups will be compared on the mean score on the frequency version of the Craving Experience Questionnaire at 1-month (primary outcome measure). Secondary outcomes include: percentage of days abstinent and longest period of continuous abstinence from cocaine (past 28-days at 1-month follow-up); urine drug screen and CUD diagnosis (DSM-5).
We will conduct a full external pilot RCT of a novel, MFCT for CUD. The findings will inform the case, and necessary modifications, for a substantive study.
可卡因使用障碍(CUD)是一种使人衰弱的病症,其特征在于与可卡因相关的适应不良记忆以及认知和行为控制受损。目前尚无经证据支持的药物疗法,且针对CUD的心理干预效果也很微弱。我们新的聚焦记忆认知疗法(MFCT)旨在改变与可卡因相关的记忆,以减少渴望和药物使用。
这是一项单中心(门诊)、为期15周的双臂试点随机对照试验(RCT),旨在探讨可行性、安全性、质量和初步疗效。30名参与者(年龄≥18岁的成年人;当前患有CUD)在研究期间将接受持续的标准护理(照常治疗[TAU]),并将被随机(1:1)分为对照组或干预组。对照组将接受3次90分钟的CUD认知病例概念化评估和2次30分钟的可卡因相关线索诱导程序(呈现图像和物品)。实验组参与者将接受3次90分钟的CUD认知病例概念化评估;2次30分钟的线索诱导程序;以及个体MFCT(5次120分钟;每天1次,共1周;并在3个月内进行3次预防复发随访)。所有研究参与者将在1周、1个月和3个月时完成研究随访。将比较实验组和对照组在1个月时渴望体验问卷频率版的平均得分(主要结局指标)。次要结局包括:戒断天数百分比和从可卡因中持续戒断的最长时间(在1个月随访时过去28天);尿液药物筛查和CUD诊断(《精神疾病诊断与统计手册》第5版)。
我们将对一种用于CUD的新型MFCT进行全面的外部试点RCT。研究结果将为实质性研究的情况及必要修改提供依据。